Logo

Isis Extends Antisense Drug Discovery Collaboration With Lilly

May 06, 2004

NEW YORK, May 6 (GenomeWeb News) - Isis Pharmaceuticals announced today that it is extending its collaboration with Eli Lilly to develop antisense-based cancer therapeutics.

 

Under the collaboration, which was originally forged in June 2002, the companies will continue to characterize and develop RNaseH, siRNA, and splicing modulating inhibitors as potential treatments, Isis said. In addition, the companies will explore the use of RNA-directed technology to find potential anticancer drug targets.

 

Financial terms of the extension were not disclosed.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.